NAD+ (Nicotinamide Adenine Dinucleotide) vs Orforglipron (LY-3502970)
Updated October 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of NAD+ (Nicotinamide Adenine Dinucleotide) and Orforglipron (LY-3502970) (also searched as Orforglipron (LY-3502970) vs NAD+ (Nicotinamide Adenine Dinucleotide)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
NAD+ (Nicotinamide Adenine Dinucleotide) centers on metabolic, while Orforglipron (LY-3502970) leans toward metabolic. On indexed research, NAD+ (Nicotinamide Adenine Dinucleotide) is ahead (NAD+ (Nicotinamide Adenine Dinucleotide): 46 studies, Human evidence; Orforglipron (LY-3502970): 36, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •NAD+ (Nicotinamide Adenine Dinucleotide) is strongest for metabolic; Orforglipron (LY-3502970) for metabolic.
- •Evidence: NAD+ (Nicotinamide Adenine Dinucleotide) Human evidence (46 studies) vs Orforglipron (LY-3502970) Human clinical (36).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Metabolic | Energy production and cellular repair
GLP-1 Agonist | Type 2 Diabetes and Obesity
NAD+ (Nicotinamide Adenine Dinucleotide) vs Orforglipron (LY-3502970): side-by-side
| Metric | NAD+ (Nicotinamide Adenine Dinucleotide) | Orforglipron (LY-3502970) |
|---|---|---|
| Class | Metabolic | Metabolic |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 46 | 36 |
| Research level | Well Studied | FDA Approved |
| Strongest effect | Metabolic & appetite | Metabolic & appetite |
| Healing & recovery | 3.0▲ | 2.0 |
| Muscle & body comp | 1.0▲ | 1.0▲ |
| Metabolic & appetite | 4.0 | 5.0▲ |
| Neuro & mood | 4.0▲ | 2.0 |
| Sleep & circadian | 1.0 | 2.0▲ |
| Inflammation & immune | 3.0▲ | 3.0▲ |
| Skin & aesthetics | 2.0 | 3.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | NAD+ (Nicotinamide Adenine Dinucleotide) | Orforglipron (LY-3502970) |
|---|---|---|
| Mechanism | Electron carrier in redox reactions | GLP-1 receptor agonist |
| Route | Intravenous infusion | Oral |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is NAD+ (Nicotinamide Adenine Dinucleotide)?
NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.
Full NAD+ (Nicotinamide Adenine Dinucleotide) profile, mechanism & studies →What is Orforglipron (LY-3502970)?
Orforglipron (LY-3502970) is an investigational oral small-molecule GLP-1 receptor agonist studied for type 2 diabetes and obesity, offering pill-based dosing without injection.
Full Orforglipron (LY-3502970) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | NAD+ (Nicotinamide Adenine Dinucleotide) | 3.0/5 effect signal |
| Muscle | Even | Both ~1.0/5 |
| Metabolic | Orforglipron (LY-3502970) | 5.0/5 effect signal |
| Neuro | NAD+ (Nicotinamide Adenine Dinucleotide) | 4.0/5 effect signal |
| Sleep | Orforglipron (LY-3502970) | 2.0/5 effect signal |
| Inflammation | Even | Both ~3.0/5 |
| Skin | Orforglipron (LY-3502970) | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack NAD+ (Nicotinamide Adenine Dinucleotide) and Orforglipron (LY-3502970)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
NAD+ (Nicotinamide Adenine Dinucleotide) vs Orforglipron (LY-3502970): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
NAD+ (Nicotinamide Adenine Dinucleotide) has 46 approved studies indexed (Human evidence), and Orforglipron (LY-3502970) has 36 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is NAD+ (Nicotinamide Adenine Dinucleotide) or Orforglipron (LY-3502970) better?
It depends on your goal. NAD+ (Nicotinamide Adenine Dinucleotide) is strongest for metabolic; Orforglipron (LY-3502970) for metabolic. NAD+ (Nicotinamide Adenine Dinucleotide) has more indexed studies (46). See the goal-by-goal breakdown above.
Is NAD+ (Nicotinamide Adenine Dinucleotide) or Orforglipron (LY-3502970) better for weight loss?
Orforglipron (LY-3502970) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is NAD+ (Nicotinamide Adenine Dinucleotide) or Orforglipron (LY-3502970) better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, NAD+ (Nicotinamide Adenine Dinucleotide) or Orforglipron (LY-3502970)?
NAD+ (Nicotinamide Adenine Dinucleotide) has 46 approved studies indexed (Human evidence); Orforglipron (LY-3502970) has 36 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack NAD+ (Nicotinamide Adenine Dinucleotide) and Orforglipron (LY-3502970)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of NAD+ (Nicotinamide Adenine Dinucleotide) vs Orforglipron (LY-3502970)?
NAD+ (Nicotinamide Adenine Dinucleotide): no community-reported effects logged yet. Orforglipron (LY-3502970): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is NAD+ (Nicotinamide Adenine Dinucleotide) or Orforglipron (LY-3502970) FDA-approved?
NAD+ (Nicotinamide Adenine Dinucleotide) is a research-use compound and is not FDA-approved. Orforglipron (LY-3502970) is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Orforglipron (LY-3502970) better than NAD+ (Nicotinamide Adenine Dinucleotide)?
For metabolic, Orforglipron (LY-3502970) has the edge; for metabolic, NAD+ (Nicotinamide Adenine Dinucleotide) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed October 27, 2026.